This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. Zanubrutinib demonstrated sustained efficacy in CLL with del(17p), emphasizing the importance of BTK inhibitors in high-risk hematologic malignancies.
Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone. Barriers to finerenone integration include cost, access, and existing MRA underutilization, with pharmacists crucial in educating prescribers and patients.
Because of their ability to cover a wide array of bacteria, low adverse effect profile, and oral availability, cephalosporins are commonly used in the treatment of outpatient infections. Of note, only first-, second-, and third-generation cephalosporins are available as oral formulations.
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.
3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1.
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. The study found no significant differences in biosimilar use by age, race, or ethnicity, but regional variations existed. SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.
Understanding and addressing barriers to medication adherence are crucial for effective treatment of psychiatric disorders and improving patient outcomes. Long-acting injectable antipsychotics may improve adherence in homeless populations, but transportation and clinic visit logistics must be considered.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Upon sensing dsRNA, the cell effectively halts protein synthesis, thereby preventing the virus from manufacturing the essential proteins required for its own reproduction. 1,2 The researchers believe that compounds that boost the ISR pathway could be effective candidates for antiviral drugs.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content